Invivo Therapeutics Holdings Corp (NVIV) was Initiated by Raymond James to “Strong Buy” and the brokerage firm has set the Price Target at $13. Raymond James advised their investors in a research report released on Jul 7, 2016.
On the company’s financial health, Invivo Therapeutics Holdings Corp reported $-0.20 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on May 6, 2016. Analyst had a consensus of $-0.26.During the same quarter in the previous year, the company posted $-0.24 EPS.
Invivo Therapeutics Holdings Corp closed down -0.23 points or -3.92% at $5.63 with 2,30,931 shares getting traded on Tuesday. Post opening the session at $5.83, the shares hit an intraday low of $5.53 and an intraday high of $5.83 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Aug 14, 2015, C Ann Merrifield (director) purchased 2,000 shares at $12.36 per share price.
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The Company’s technologies incorporate intellectual property licensed under an exclusive around the world license from Boston Children’s Hospital (BCH) and the Massachusetts Institute of Technology (MIT) and intellectual property that has been developed internally including in collaboration with its advisors and partners. The Company intends to leverage its platform technology to develop the Neuro-Spinal Scaffold an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury (SCI). The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.